4//SEC Filing
BELLICUM PHARMACEUTICALS, INC 4
Accession 0001358403-17-000018
CIK 0001358403operating
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 7:17 PM ET
Size
7.8 KB
Accession
0001358403-17-000018
Insider Transaction Report
Form 4
Spencer David M.
Chief Scientific Officer
Transactions
- Award
Restricted Stock Units
2017-01-03+6,250→ 6,250 total→ Common Stock (6,250 underlying) - Award
Employee Stock Option (right to buy)
2017-01-03+11,250→ 11,250 totalExercise: $13.89Exp: 2027-01-02→ Common Stock (11,250 underlying)
Footnotes (3)
- [F1]25% of the shares subject to the stock option vest and become exercisable on January 3, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- [F2]Each restricted stock unit represents a contingent right to receive one share of BLCM common stock.
- [F3]The restricted stock units vest in four equal annual installments beginning January 3, 2018.
Documents
Issuer
BELLICUM PHARMACEUTICALS, INC
CIK 0001358403
Entity typeoperating
Related Parties
1- filerCIK 0001358403
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 7:17 PM ET
- Size
- 7.8 KB